home · filing · 0001193125-21-336078
8-K filed November 22, 2021, 6:59 PM ET
ticker TNYA
CIK 0001858848
leadership
confidence high
sentiment neutral
materiality 0.40
Tenaya Therapeutics appoints Dr. June Lee to board; Dr. JeenJoo Kang resigns
Tenaya Therapeutics, Inc.
Dr. June Lee appointed as Class III director, term expiring at 2024 annual meeting.
Dr. Lee receives annual cash retainer of $35,000 and stock option grant with ~$320,000 fair value.
Dr. Lee most recently CEO of Esker Therapeutics; previously EVP at MyoKardia advancing cardiomyopathies.
Dr. JeenJoo Kang resigned voluntarily, not due to any disagreement, to focus on CEO role at Appia Bio.
Company highlights transition to clinical-stage and Dr. Lee's relevant development experience.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2021-11-17
Filed November 22, 2021, 6:59 PM ET
On November 17, 2021, JeenJoo Kang, Ph.D., submitted her resignation as a director of Tenaya Therapeutics, Inc.
Effective 2021-11-19
Filed November 22, 2021, 6:59 PM ET
On November 19, 2021, the Board appointed June Lee, M.D., to serve as a Class III director
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
JeenJoo Kang resigned as Director at Tenaya Therapeutics, Inc..
Action resigned
Role Director
Exact text from the filing
On November 17, 2021, JeenJoo Kang, Ph.D., submitted her resignation as a director of Tenaya Therapeutics, Inc.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
June Lee was appointed as Director at Tenaya Therapeutics, Inc..
Action appointed
Role Director
Exact text from the filing
On November 19, 2021, the Board appointed June Lee, M.D., to serve as a Class III director
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-21-336078
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.